Back to resultsA Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
Primary Purpose
Open-angle Glaucoma, Ocular Hypertension
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Brinzolamide/Timolol
Sponsored by
About this trial
This is an interventional treatment trial for Open-angle Glaucoma
Eligibility Criteria
Inclusion Criteria: Adults of either sex and any race diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) Exclusion Criteria: Under 18
Sites / Locations
- Fort Worth and Other Sites
Outcomes
Primary Outcome Measures
Ocular discomfort
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00326092
Brief Title
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
Official Title
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
September 2007
Overall Recruitment Status
Completed
Study Start Date
May 2006 (undefined)
Primary Completion Date
August 2006 (Actual)
Study Completion Date
August 2006 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alcon Research
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to assess the comfort of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Open-angle Glaucoma, Ocular Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
88 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Brinzolamide/Timolol
Primary Outcome Measure Information:
Title
Ocular discomfort
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adults of either sex and any race diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component)
Exclusion Criteria:
Under 18
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Julia White
Organizational Affiliation
Study Director
Official's Role
Study Director
Facility Information:
Facility Name
Fort Worth and Other Sites
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76134
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
19049301
Citation
Vold SD, Evans RM, Stewart RH, Walters T, Mallick S. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2008 Dec;24(6):601-5. doi: 10.1089/jop.2008.0030.
Results Reference
result
Learn more about this trial
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
We'll reach out to this number within 24 hrs